Abstract: The present invention provides novel methods for diagnosing a state of health based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls.

Abstract: The present invention provides novel methods for diagnosing diseases based on the determination of specific miRNAs that have altered expression levels in disease states compared to healthy controls.

Abstract: The invention relates to methods for diagnosing Parkinson's Disease PAD) with miRNA markers. Towards the identification of biomarkers for diagnosis of PD, a comprehensive analysis of miRNA expression patterns was obtained. Significantly deregulated miRNAs were identified.

Abstract: MicroRNAs (miRNA) are a recently discovered class of small non-coding RNAs (17-14 nucleotides). Due to their function as regulators of gene expression they play a critical role both in physiological and in pathological processes, such as cancer. The present invention provides novel methods for diagnosing a state of health based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls.

Abstract: The invention relates to novel miRNA markers useful for diagnosis or therapy of disease, in particular for neuronal disorders such as Alzheimer's Disease (AD).

Abstract: A process for preparing 4-cyclohexyl-2-methyl-2-butanol, comprising: a) reaction of styrene with isopropanol at elevated temperature to obtain 2-methyl-4-phenyl-2-butanol, and b) heterogeneously catalyzed hydrogenation of 2-methyl-4-phenyl-2-butanol over a catalyst suitable for ring hydrogenation of aromatics, where the molar ratio of the styrene used in step a) to the isopropanol used in step a) is in the range from 1:below 5 to 1:0.5.

Abstract: A process for preparing salts of acrylamido-2-methylpropanesulfonic acid (A) using the steps of: preparing a solution of a contaminated salt of acrylamido-2-methyl-propanesulfonic acid (A) in an anhydrous organic solvent (L) using at least one basic component (B) selected from the group of alkali metal oxides, alkaline earth metal oxides, alkali metal hydroxides, alkaline earth metal hydroxides and amines of the formula (I) NRaRbRc??(I) where the Ra, Rb and Rc radicals are each independently: hydrogen, C1-C4-alkyl, hydroxy-C1-C4-alkyl or C1-C4-alkoxy, where the molar ratio of compound (A) to the basic component (B) is 1:1 to 1:3, recovering the dissolved salt of compound (A) by crystallization or by precipitation, by altering the temperature and/or the pressure and/or the concentration of the salt in the solution. This leads to salts which are low in by-products and are particularly suitable for polymerization.

Abstract: The invention relates to a method and kit for enriching miRNA nucleic acids molecules of interest in a sampe by selective removal of nucleic acid species, in particular miRNA species, which are not of interest. The invention is based on the surprizing and previously unknown information that only a few individual miRNA species make up the majority of all miRNA species in a sample. Selective removal of these species prior to detection of miRNA nucleic acids molecules will improve assay time, assay sensitivity, and reproducibility.

Abstract: A process for preparing 4-cyclohexyl-2-methyl-2-butanol, comprising: a) reaction of styrene with isopropanol at elevated temperature to obtain 2-methyl-4-phenyl-2-butanol, and b) heterogeneously catalyzed hydrogenation of 2-methyl-4-phenyl-2-butanol over a catalyst suitable for ring hydrogenation of aromatics, where the molar ratio of the styrene used in step a) to the isopropanol used in step a) is in the range from 1:below 5 to 1:0.5.

Abstract: The invention relates to methods for diagnosing multiple sclerosis with miRNA markers. Diagnosis of multiple sclerosis (MS) can be challenging in patients with atypical presentations and during a first neurological deficit possibly related to inflammatory demyelination. Towards the identification of biomarkers for diagnosis of MS, a comprehensive analysis of miRNA expression patterns was obtained. Significantly deregulated miRNAs were identified, which have previously not been related to MS according to the microRNA disease database. These miRNAs could potentially serve as future diagnostic biomarkers for MS and help in diagnosis, monitoring disease activity, and evaluation of treatment responses in patients with MS.

Abstract: The present invention relates to non-invasive methods for early diagnosis and/or differential diagnosis of acute myocardial infarction in a blood sample of a subject. Further, the present invention relates to polynucleotides or sets of polynucleotides for detecting miRNAs or sets of miRNAs for early diagnosis and/or differential diagnosis of acute myocardial infarction in a blood sample of a subject.

Abstract: The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of a disease in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of a disease in a body fluid sample from a subject.

Abstract: The invention relates to a method of detecting nucleic acid molecules by immunoassay detection. Detection of a specific nucleic acid molecule of interest is achieved by using a nucleic acid probe in solution which hybridizes in solution to the nucleic acid molecule of interest. Immunoassay detection is achieved by using an antibody specific for the hybrid formed by hybridization of the nucleic acid probe to the nucleic acid molecule of interest.

Abstract: The present invention relates to methods of determining whether a patient responds to a therapeutic treatment of multiple sclerosis (MS), of monitoring the course of multiple sclerosis (MS) in a patient, of determining the risk for a relapse of multiple sclerosis (MS) in a patient, and of adjusting the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient. Said methods are based on the determination of the level of at least one miRNA in a test sample isolated from the patient. The present invention also relates to a method of identifying a compound suitable for the treatment of multiple sclerosis in a patient.

Abstract: MicroRNAs (miRNA) are a recently discovered class of small non-coding RNAs (17-14 nucleotides). Due to their function as regulators of gene expression they play a critical role both in physiological and in pathological processes, such as cancer. The present invention provides novel methods for diagnosing a state of health based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls.

Abstract: The present invention relates to improved powderous formulations of organic acids or esters having an aromatic ring system, as well as to the production of such formulations.

Abstract: A folding table for attachment to the rear side of a vehicle seat part has a fastening device (2a, 2c) for fastening the folding table to the vehicle seat (1a, 1b, 1c), a carrier element (4) which is connected to the fastening device (2a, 2c) and extends downward from the fastening device (2a, 2c) and a tabletop (6) rotatably connected to the carrier element (4). Supporting elements (7e) are arranged on the tabletop (6) which, when the tabletop (6) is in the working position, can be moved in the direction toward the vehicle seat part (1a, 1b, 1c) by a common actuating member (7a, 7d, 7b?, 7b?) and can be fixed in different positions by a manually releasable latching device (6h, 7b, 7c), so that the tabletop (6) can be aligned in a horizontal position.

Abstract: What is described is a process and an installation for drying articles, in particular painted vehicle bodies, in which the articles are moved through a drying zone in which they are hardened in an inert-gas atmosphere. Inert gas is taken from the drying zone constantly or intermittently and is first of all conducted along a first face which is at a first temperature at which higher-boiling contaminants condense out. The condensate that forms in the process is discharged. After that, the inert gas which has been pre-cleaned in this way is conducted along at least one second face which is at a lower temperature than the first face. Lower-boiling contaminants are precipitated at this point. These condensates, too, are then discharged. This process and installation work more favorably, energy-wise, and with higher cleaning efficiency than known processes and installations of a similar type.

Abstract: The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of psoriasis in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of psoriasis in a body fluid sample from a subject. In addition, the present invention relates to sets of miRNAs for diagnosing and/or prognosing of psoriasis in a body fluid sample from a subject.

Abstract: The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of colon cancer in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of colon cancer in a body fluid sample from a subject. In addition, the present invention relates to sets of miRNAs for diagnosing and/or prognosing of colon cancer in a body fluid sample from a subject.